Latest Headlines
-
Affidea Acquires A Majority Stake In LabPoint From Lindenhofgruppe, Strengthening Its Diagnostics And Laboratory Medicine Capabilities
1/14/2026
Affidea Group, Europe’s leading provider of advanced diagnostics, community-based polyclinics and specialised healthcare services including oncology, announces the acquisition of a majority stake in LabPoint S.A. from Lindenhofgruppe.
-
CancerIQ Unveils A Risk-Based Early Cancer Detection Program For Imaging & Diagnostics
1/13/2026
CancerIQ, the leading precision health company focused on cancer early detection, today announced a new risk-based early cancer detection program designed to help diagnostics and imaging companies — and the providers who use their technologies — match the right people to the right screening approaches and get those tests completed at scale.
-
Labcorp Expands MRD Testing For Breast, Lung And Colon Cancer Recurrence Risk
1/13/2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging.
-
HCAP Partners Announces Follow-On Acquisition For Integrated Diagnostic Services (IDS) With The Addition Of Core Analytics Lab & Radiology
1/13/2026
HCAP Partners, a California-based private equity firm and nationally recognized impact investor, today announced a follow-on acquisition for its Integrated Diagnostic Services (IDS) platform with the addition of Core Analytics Lab & Radiology (Core), a leading provider of mobile radiology and laboratory services across California.
-
Synthego Announces Entry Into Molecular Biology And Clinical Diagnostic Reagents Market
1/13/2026
Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego's significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality, reliable reagents designed to accelerate the development and deployment of cutting-edge diagnostic tests.
-
Freenome Announces Expanded Artificial Intelligence And Deep Learning Initiatives Accelerated By NVIDIA, To Advance Personalized Multi-Cancer Detection
1/12/2026
Freenome today announced an initiative to advance its blood-based early cancer screening program by leveraging NVIDIA deep learning technology and expertise to improve the recognition of cancer-specific patterns in the blood at the disease’s earliest stages.
-
Alamar Biosciences Announces Launch Of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection In Alzheimer's Disease Research
1/12/2026
Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay.
-
10x Genomics To Advance Research In Diagnostic Applications Of Tumor Single Cell And Spatial Profiling
1/12/2026
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression.
-
Truvian Health Rapidly Expands TruVerus Menu With FDA Clearances For Cardiovascular, Liver, And Core Metabolic Health Tests
1/12/2026
Truvian Health (“Truvian”), a transformational diagnostics company redefining healthcare, today announced it has received 510(k) clearances (K251091, K251074, K251157) from the U.S. Food and Drug Administration (FDA) for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.
-
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI To Advance Scientific Instrumentation And Accelerate Laboratory Performance
1/12/2026
Thermo Fisher Scientific Inc. the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale.